ACP2: A Promising Drug Target and Potential Biomarker for Ovarian Cancer

Target Name: ACP2

NCBI ID: G53

ACP2

ACP2: A Promising Drug Target and Potential Biomarker for Ovarian Cancer

Ovarian cancer is a leading cause of cancer death in women, affecting an estimated 21,120 women in the United States alone in 2020. Despite advances in surgical and radiation treatments, the survival rate for ovarian cancer has remained largely unchanged in recent years. Therefore, there is a growing need for new treatments and biomarkers to improve outcomes for ovarian cancer patients.

ACP2, a protein that belongs to the Aquaporin (AQP) family, has been identified as a potential drug target and biomarker for ovarian cancer. In this article, we will discuss the ACP2 protein, its functions, and its potential as a drug target and biomarker for ovarian cancer.

ACP2: AQP2-Containing Proteins

ACP2 is a 22-kDa protein that is expressed in various tissues and organs, including the brain, heart, kidneys, and reproductive organs. It is a member of the AQP2 family, which includes other water-exciting proteins, such as AQP1 and AQP3. The AQP2 family plays a crucial role in the regulation of water transport and has been implicated in various physiological processes, including blood pressure, blood flow, and tissue perfusion.

Function of ACP2

ACP2 is involved in the regulation of a variety of physiological processes that are critical for cancer progression, including cell survival, angiogenesis, and invasion.

1. Cell Survival and Proliferation

Studies have shown that ACP2 is involved in the regulation of cell survival and proliferation. In cancer cells, ACP2 has been shown to promote cell survival by inhibiting cell apoptosis and promoting cell cycle progression. This is associated with the development of resistance to chemotherapy and the poor prognosis for cancer patients.

1. Angiogenesis

ACP2 is also involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed to supply oxygen and nutrients to the growing tumor. The deregulation of angiogenesis has been implicated in cancer progression and the development of new blood-supply routes can contribute to tumor growth and the development of invasive tumors.

1. Invasion

In addition to its role in cell survival and angiogenesis, ACP2 has also been shown to contribute to the invasive properties of cancer cells. By regulating the cell adhesion molecule E-cadherin, ACP2 has been shown to promote the migration and invasion of cancer cells.

Potential as a Drug Target

The identification of ACP2 as a potential drug target and biomarker for ovarian cancer has led to a new understanding of the underlying mechanisms of this disease. Currently, several small molecules have been shown to interact with ACP2 and enhance the inhibition of ACP2-mediated signaling pathways. These small molecules include compounds that have been shown to inhibit the activity of ACP2 in cell culture models of ovarian cancer.

One of the most promising compounds is GX491, a small molecule that binds to ACP2 with high affinity. GX491 has been shown to inhibit the activity of ACP2 in cell culture models of ovarian cancer and has been shown to have anti-tumor effects in animal models of ovarian cancer.

In addition to GX491, several other small molecules have also been shown to interact with ACP2 and enhance the inhibition of ACP2-mediated signaling pathways. These molecules include inhibitors of ACP2-mediated signaling pathways, such as the PI3K/AQP2 pathway, which is involved in the regulation of angiogenesis and the PI3K/AQP3 pathway, which is involved in the regulation of cell survival and proliferation.

Potential as a Biomarker

The identification of AC

Protein Name: Acid Phosphatase 2, Lysosomal

The "ACP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets